Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 3/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 3/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | STK10 | O94804 | 1/20 | 0.36 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153479 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1CA1CA2CA3 | |
| SCHEMBL6153477 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1CA1CA2CA3 | |
| SCHEMBL6153878 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1CA1CA2CA3 | |
| SCHEMBL6154397 | 0.81 | LRRK2 (0.49) | ROCK2CA1CA2CA3CA6 | |
| SCHEMBL6154410 | 0.81 | LRRK2 (0.49) | ROCK2CA1CA2CA3CA6 | |
| SCHEMBL12316370 | 0.80 | CA1 (0.51) | CA1CA2CA3CA6CA7 | |
| SCHEMBL6154101 | 0.79 | ROCK2 (0.80) | ROCK2ROCK1CA1CA2CA3 | |
| SCHEMBL1584269 | 0.79 | ROCK2 (0.80) | ROCK2ROCK1CA1CA2CA3 | |
| SCHEMBL1584266 | 0.79 | ROCK2 (0.80) | ROCK2ROCK1CA1CA2CA3 | |
| SCHEMBL6153305 | 0.79 | CA1 (0.47) | CA1CA2CA3CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046339-B1 | RHO/ROCK/P13/AKT KINASE INHIBITORS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PROTOZOAN PARASITES | UNIV PARIS CURIE (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-20090203678-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROTOZOAN PARASITIC DISEASES | UNIVERSITE PIERRE ET MARIE CURIE-PARIS VI (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090203678-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROTOZOAN PARASITIC DISEASES | UNIVERSITE PIERRE ET MARIE CURIE-PARIS VI (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1891958-A1 | Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites. | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2008-02-27 | — | — | EP | disclosed |
| WO-2008015001-A1 | RHO/ROCK/P13/AKT KINASE INHIBITORS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PROTOZOAN PARASITES | UNIVERSITE PIERRE ET MARIE CURIE-PARIS VI (FR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203678-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROTOZOAN PARASITIC DISEASES | RHOA, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CA1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.